Economics
EB101.R24: 1998 WHO EB proposal for the WHO Revised drug strategy
Submitted by James Love on 26. August 2010 - 12:02101st Session
EB101.R24
Agenda item 9
27 January 1998
Revised drug strategy
The Executive Board
RECOMMENDS to the Fifty-first World Health Assembly the adoption of the following resolution:
The Fifty-first World Health Assembly,
Recalling resolutions WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14;
Having considered the report of the Director-General on the revised drug strategy[1];
Sources for Researching Drug Prices
Submitted by Anne Mira Guha on 10. August 2010 - 14:27The following are links to web pages with prices of prescription drugs.
Australia
Schedule Pharmaceutical Benefits
http://www.pbs.gov.au/html/home page
Austria
The Common European Drug Database (CEDD)
http://cedd.oep.hu/
Bahrain
Ministry of Health
http://www.moh.gov.bh/EN/E-ervices/DrugPrices.aspx
Belgium
Institut national d'assurance maladie-invalidit? / Rijksinstituut voor ziekte- en invaliditeitsverzekering
http://www.inami.fgov.be/
Brazil
Banco de Precos Em Saude
Data points on price of medical technologies
Submitted by Anne Mira Guha on 10. August 2010 - 14:12The WHO EWG's proposals for taxes to fund medical R&D
Submitted by James Love on 13. January 2010 - 19:00Some surprising taxes, and evidence of IFPMA lobbying
Reimbursement Categories of Medicines in European Union Member Countries
Source: EUROMEDSTAT (http://www.euromedstat.cnr.it/reports/reports_reimbursement_categories.asp)
AUSTRIA
"Heilmittelverzeichnis": Pharmaceuticals listed on the "Heilmittelverzeichnis" (Pharmaceutical List) qualify for automatic reimbursement (100%)
AUSTRIA
"Heilmittelverzeichnis": Pharmaceuticals listed on the "Heilmittelverzeichnis" (Pharmaceutical List) qualify for automatic reimbursement (100%)
Drug Pricing
Tuesday, 24 July 2007
Second Generation Antiretrovirals
For older documents on second generation antiretrovirals (including both second line drugs and drugs from the revised WHO recommendations for first-line therapy in resource-poor settings), see the CPTech page on Second-Generation Antiretrovirals.
Economics of Creativity and Knowledge
Submitted by James Love on 12. August 2009 - 16:49Auren Hoffman on productivity gains from open source software
Submitted by James Love on 26. June 2009 - 14:16According to Rapleaf CEO and venture capitalist Auren Hoffman, open source software has dramatically increased the productivity of software engineers. In a June 23, 2009 article in Tech Crunch titled “Engineers Are The Best Deal – So Stock Up On Them,” Hoffman writes:
PAHO dispute standards for transparency of economic data for pharmaceutical industry
Submitted by James Love on 25. June 2009 - 10:49Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:
FDA Priority Review Voucher, KEI comments
Submitted by James Love on 22. December 2008 - 10:11KEI filed comments on Friday on the FDA request for comments on the Priority Review Voucher.
